New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export TVRD’s income statement to Excel — free account
Tvardi Therapeutics, Inc.
TVRDTvardi Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7.1 million, down 66.0% from fiscal 2023.
- Revenue
- +20.3%
- EPS
- n/m
- Free cash flow
- n/m
Quarter to September 2026, against a year earlier
0.99
0.04
+4.21%
After hours trading: 0.97, down 2.02%, last trade Fri 7:28pm Eastern.
Follow TVRD
Alert me
Ratios over time Q4 FY25 to Q3 FY26
Returns on capital
ROIC was 0.00% in Q3 FY26, the highest of these four quarters.
ROEROIC
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| ROE | 51.9% | −480.1% | −126.2% | −123.1% |
| ROIC | 0.0% | 0.0% | 0.0% | 0.0% |
Debt
Net debt is 3.53× a year’s EBITDA. Debt is 0.00× equity.
Debt / equityNet debt / EBITDA
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Debt / equity | 0.0× | 0.0× | 0.0× | 0.0× |
| Net debt / EBITDA | 4.0× | 3.6× | 2.4× | 3.5× |
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
2.79 | 2.22 | 1.73 | 2.76 | |
Current Ratio |
2.86 | 2.25 | 1.87 | 2.86 | |
Net Debt/EBITDA |
3.97 | 3.56 | 2.39 | 3.53 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.78 | 0.86 | 1.43 | 1.04 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.02 | 0.01 | |
Free Cash Flow Yield |
— | — | — | — | |
Operating CF per Share |
(0.77) | (0.62) | (0.98) | (0.50) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.77) | (0.62) | (0.98) | (0.50) | |
Cash per Share |
4.15 | 2.66 | 1.68 | 1.76 | |
Shareholders Equity per Share |
2.82 | 1.55 | 0.89 | 1.22 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.82 | 1.55 | 0.89 | 1.22 | |
Free Cash Flow |
(5.68) | (5.86) | (9.23) | (6.38) | |
Working Capital |
20.50 | 14.07 | 7.96 | 15.05 | |
Net Current Asset Value |
20.41 | 14.01 | 7.93 | 15.05 | |
| Other line items | |||||
Average Payables |
5.60 | 3.40 | 3.53 | 3.08 | |
Average Assets |
33.64 | 32.38 | 30.63 | 31.28 | |
Average Common Equity |
(35.09) | 3.22 | 20.65 | 21.66 |
Columns are period end dates · fundamentals updated Nov 17, 2026